Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>
Marta Milà‐Alomà(University of California, San Francisco), Karine Fauria(Pasqual Maragall Foundation), José María Gónzalez‐de‐Echávarri(Pasqual Maragall Foundation), Gonzalo Sánchez‐Benavides(Pasqual Maragall Foundation), Kaj Blennow(Sahlgrenska University Hospital), José Luís Molinuevo(Pasqual Maragall Foundation), Eider M. Arenaza‐Urquijo(Pasqual Maragall Foundation), Aleix Sala‐Vila(Instituto de Salud Carlos III), Gemma Salvadó(Lund University), Juan Domingo Gispert(Lund University), Oriol Grau‐Rivera(Pasqual Maragall Foundation), Gwendlyn Kollmorgen(Roche Pharma AG (Germany)), Henrik Zetterberg(University of Wisconsin–Madison), Maryline Simon(Roche (Switzerland)), Natàlia Vilor‐Tejedor(Radboud University Nijmegen), Marta Crous‐Bou(Harvard University), Marc Suárez‐Calvet(Pasqual Maragall Foundation), Carolina Minguillón(Pasqual Maragall Foundation)
Cited by 260
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k